Wednesday, March 18, 2015 5:28:37 PM
March 6, 2015
Tags: cbd, fda warning
Although plenty of businesspeople in the cannabis community regard various properties of the plant as effective medicine for a number of ailments, the U.S. Food and Drug Administration doesn’t necessarily agree.
The agency recently sent six strictly-worded warning letters to companies across the country that peddle CBD-based products, telling all that they need to quit making medicinal claims or face legal action.
“Your products are not generally recognized as safe and effective for the above referenced uses and, therefore, these products are ‘new drugs,'” the FDA wrote to CBD Life Holdings in Arizona. “New drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from the FDA…You should take prompt action to correct the violations cited in this letter.”
Similar letters were sent to Hemp Oil Care in California, Twin Falls Bio Tech in South Carolina, and three Washington State companies: Purecbd.net, Canna Pet, and Canna Companion.
The companies were all warned to take action to rectify problems the FDA identified within 15 working days of receiving the letters.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM